Drug Profile
PMS 601
Alternative Names: MFH 1; PMS601Latest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator French Atomic Energy Commission; Institut Paris-Sud sur les Cytokines; University of Paris VII
- Developer BTG; French Atomic Energy Commission; Institut Paris-Sud sur les Cytokines; University of Paris VII
- Class Antivirals; Piperazines
- Mechanism of Action Platelet activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 14 Mar 2007 Preclinical development is ongoing
- 14 Mar 2007 Data presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI-2007) added to the adverse events and Viral Infections pharmacodynamics section